SCHEMBL1633719

SCHEMBL1633719

CCOC(=S)Sc1ccc(Cl)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
MAPT P10636 5/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 3/20 0.37
ALOX12 P18054 3/20 0.37
KMT2A Q03164 3/20 0.37
NPSR1 Q6W5P4 3/20 0.37
HPGD P15428 2/20 0.37
MAPK1 P28482 2/20 0.37
USP2 O75604 1/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 4/20 0.36
KDM4E B2RXH2 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28573075 0.88 LMNA (0.41) ALDH1A1MAPTL3MBTL1MEN1ALOX12
SCHEMBL596873 0.83 MCL1 (0.36) ALDH1A1MAPTL3MBTL1MEN1KMT2A
SCHEMBL1632856 0.81 MAPT (0.35) ALDH1A1MAPTL3MBTL1MEN1KMT2A
SCHEMBL595968 0.79 HTT (0.40) ALDH1A1MAPK1HTTKDM4EHDAC3
SCHEMBL16010505 0.78 ALDH1A1 (0.45) ALDH1A1MAPTL3MBTL1MEN1KMT2A
SCHEMBL27719945 0.78 SMN1; SMN2 (0.34) ALDH1A1MAPTL3MBTL1KMT2AHPGD
SCHEMBL22816343 0.78 ALDH1A1 (0.35) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL16017034 0.76 HDAC3 (0.35) ALDH1A1MEN1KMT2AKDM4EHDAC3
SCHEMBL1017813 0.75 ABL1 (0.38) ALDH1A1MAPTKMT2AHPGDKDM4E
SCHEMBL4299182 0.75 MEN1 (0.47) ALDH1A1MAPTMEN1ALOX12KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-20060241302-A1 Morpholine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-10-26 US disclosed
EP-1640366-A1 HETEROCYCLIC METHYL SULFONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241302-A1 Morpholine derivatives APP, BACE1, SMS ALDH1A1 3313/4885MAPT 129/4885L3MBTL1 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.